Excess mortality in patients with asthma on long-acting β 2-agonists

European Respiratory Journal

Volumn 28, Issue 5, 2006, Pages 900-902

  Hasford, J ^a   Virchow, J C ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; ISOPRENALINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE;

ASTHMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HUMAN; MEDICAL RESEARCH; METERED DOSE INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED KINGDOM; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33846653188     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00085606     Document Type: Editorial

References (17)

1. World Health Organization. The World Health Report 2003. Geneva, WHO, 2004.
2. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
3. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-930.
4. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70-74.
5. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004; 140: 802-813.
6. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-2321.
7. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1595-1610.
8. Kallergis EM, Manios EG, Kanoupakis EM, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005; 127: 2057-2063.
9. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45: 170-175.
10. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46: 105-111.
11. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-506.
12. Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279-285.
13. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 139: 15-26.
14. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-1037.
15. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol 1999; 103: 427-435.
16. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metereddose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19-27.
17. Wolfe J, Laforce C, Friedman B, et al. Formoterol, 24 μg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129: 27-38.